Reviving Everyday Health with Global Scale and Sustainable Purpose
Born from the consumer care wings of GSK and Pfizer, Haleon plc emerged onto the public stage in mid‑2022 as a standalone titan in consumer health. Now headquartered in Weybridge, England, this FTSE 100 company commands a £11.2 billion global business—anchored by brands such as Sensodyne, Panadol, Advil, and Centrum.
Following its demerger, Haleon swiftly impressed investors: shedding legacy debt, repurchasing stock, and refreshing its executive lineup. In March 2025, Pfizer divested its remaining 7.3% stake, raising £2.5 billion—a move that cemented BlackRock as its largest shareholder.
A Record-Breaking Year Through Science and Efficiency
Haleon’s full-year 2024 results tell the tale of reinvention—with £11.2 billion in sales (+5% organic growth) and operating profit rising nearly 10%. Its market-leading brands not only held share—they gained it across 71% of their key segments. The company also committed £500 million to a 2025 stock buyback, underscoring financial discipline and market confidence.
Empowered by innovation, Sensodyne Clinical White launched across markets, backed by clinical proof of delivering two shades whiter teeth without increased sensitivity. Meanwhile, Panadol Dual Action and enhancements to Centrum and Voltaren showcased a product roll-out strategy built on science and consumer trust.
Expanding Oral Health R&D at the Brooklands Site
Home to Sensodyne and Corsodyl research, Weybridge’s Brooklands site is being transformed with a £130 million oral health innovation center due in 2027. This facility—complete with labs, consumer testing spaces, and clinical trial units—will elevate Haleon’s R&D, supporting its position in the £29 billion global oral care market.
A Strategic Path to Profitable Growth
During its inaugural Capital Markets Day, Haleon unveiled a bold roadmap: achieving cost savings of £800 million over five years, reducing working capital by 30%, and targeting high single-digit profit expansion from 2026 onwards. That announcement spurred shares 4% higher, signaling market optimism.
Sustainable by Design
Haleon is firmly committed to responsible business. Armed with a net-zero carbon strategy by 2040, it already sources 100% renewable electricity at owned sites and half of its factories generate onsite solar power. The company aims for 100% recycle-ready packaging by 2025 and a 10% reduction in virgin plastic use. The Weybridge plant itself is water-neutral, exemplifying global sustainability integration.
Its values extend beyond emissions. Haleon commits to advancing health equity—empowering 50 million individuals by 2025 through branded initiatives, literacy programs, and equitable access projects. Notably, its “Advil Pain Equity Project” advances accessible relief in the United States.
